Nkarta Inc NKTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
7.53UNCH (UNCH)
Volume
18,348
Close
7.53quote price arrow up+0.04 (+0.53%)
Volume
1,099,194
52 week range
1.28 - 16.24
Loading...
  • Open7.63
  • Day High7.77
  • Day Low7.25
  • Prev Close7.49
  • 52 Week High16.24
  • 52 Week High Date03/07/24
  • 52 Week Low1.28
  • 52 Week Low Date10/03/23

Key Stats

  • Market Cap528.54M
  • Shares Out70.19M
  • 10 Day Average Volume0.86M
  • Dividend-
  • Dividend Yield-
  • Beta0.87
  • YTD % Change14.09

KEY STATS

  • Open7.63
  • Day High7.77
  • Day Low7.25
  • Prev Close7.49
  • 52 Week High16.24
  • 52 Week High Date03/07/24
  • 52 Week Low1.28
  • 52 Week Low Date10/03/23
  • Market Cap528.54M
  • Shares Out70.19M
  • 10 Day Average Volume0.86M
  • Dividend-
  • Dividend Yield-
  • Beta0.87
  • YTD % Change14.09

RATIOS/PROFITABILITY

  • EPS (TTM)-2.40
  • P/E (TTM)-3.14
  • Fwd P/E (NTM)-3.56
  • EBITDA (TTM)-121.629M
  • ROE (TTM)-36.41%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,155,795.00%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Nkarta Inc

 

Profile

MORE
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable...
Ali Behbahani M.D.
Independent Chairman of the Board
Paul Hastings
President, Chief Executive Officer, Director
Alyssa Levin
Chief Financial and Business Officer
Ralph Brandenberger Ph.D.
Chief Technical Officer
Address
1150 Veterans Boulevard
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
LBPH
Longboard Pharmaceuticals Inc
22.81+0.85+3.87%
CELC
Celcuity Inc
17.66+1.36+8.34%
CMPS
Compass Pathways PLC
8.25-0.23-2.71%
ALLO
Allogene Therapeutics Inc
2.97+0.05+1.71%
ATXS
Astria Therapeutics Inc
9.35-0.15-1.58%